MCID: LNG039
MIFTS: 59

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Lung 12 73
Squamous Cell Lung Carcinoma 29 6
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 50 C3493
UMLS 73 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and adenocarcinoma. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Docetaxel and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2 adenocarcinoma 31.2 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3 lung cancer susceptibility 3 30.6 AKT1 BRAF EGFR FGFR3 HRAS KRAS
4 adenosquamous carcinoma 30.4 EGFR KRAS PIK3CA TP53
5 small cell carcinoma 30.3 EGFR PTEN TP53
6 thymoma 30.3 AKT1 EGFR HRAS TP53
7 breast adenocarcinoma 30.3 AKT1 EGFR KRAS PIK3CA PTEN TP53
8 intrahepatic cholangiocarcinoma 30.3 EGFR FGFR2 KRAS TP53 TUG1
9 adenoid cystic carcinoma 30.1 AKT1 HRAS KRAS PIK3CA PTEN TP53
10 small cell cancer of the lung 30.1 AKT1 EGFR PIK3CA PTEN TP53 TUG1
11 glioma 30.1 BRAF EGFR PIK3CA PTEN PVT1 TP53
12 melanoma 30.0 BRAF PTEN PVT1 SOX2-OT TP53
13 myelodysplastic syndrome 30.0 HRAS KRAS PTPN11 TERC TP53
14 cholangiocarcinoma 29.9 AKT1 BRAF EGFR KRAS PIK3CA PTEN
15 lung cancer 29.9 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
16 breast cancer 29.6 AKT1 BRAF EGFR FGFR2 HRAS KRAS
17 lung occult squamous cell carcinoma 11.3
18 lung mixed small cell and squamous cell carcinoma 11.3
19 breast squamous cell carcinoma 10.4 EGFR PIK3CA TP53
20 rare adenocarcinoma of the breast 10.4 AKT1 KRAS PIK3CA TP53
21 hemifacial hyperplasia 10.4 FGFR2 FGFR3
22 pulmonary blastoma 10.4 EGFR KRAS TP53
23 hyperplastic polyposis syndrome 10.4 BRAF KRAS TP53
24 estrogen-receptor positive breast cancer 10.4 AKT1 EGFR FGFR2 PIK3CA TP53
25 brain stem glioma 10.4 BRAF EGFR PIK3CA TP53
26 anal squamous cell carcinoma 10.4 AKT1 PIK3CA TP53
27 ovarian cancer 1 10.4 AKT1 KRAS PIK3CA TP53
28 brain ependymoma 10.4 EGFR TP53
29 mature teratoma 10.4 BRAF KRAS TP53
30 penile cancer 10.4 EGFR PIK3CA TP53
31 pharynx cancer 10.4 AKT1 EGFR TP53
32 nevus of ota 10.4 BRAF TP53
33 lynch syndrome 10.4 BRAF EGFR KRAS TP53
34 ductal carcinoma in situ 10.4 AKT1 EGFR TP53
35 dermatosis papulosa nigra 10.4 FGFR3 PIK3CA
36 plagiocephaly 10.4 FGFR2 FGFR3
37 adult hepatocellular carcinoma 10.4 PIK3CA TP53
38 bladder disease 10.4 AKT1 FGFR3 TP53
39 stomach disease 10.4 AKT1 EGFR TP53
40 paronychia 10.4 EGFR HRAS KRAS
41 apocrine adenoma 10.4 HRAS KRAS PIK3CA
42 lung benign neoplasm 10.4 EGFR HRAS KRAS TP53
43 acneiform dermatitis 10.4 EGFR HRAS KRAS PIK3CA
44 ovary adenocarcinoma 10.4 HRAS KRAS PIK3CA TP53
45 serous cystadenocarcinoma 10.4 AKT1 HRAS PIK3CA TP53
46 nasal cavity adenocarcinoma 10.4 HRAS KRAS TP53
47 cystadenocarcinoma 10.4 AKT1 HRAS PIK3CA TP53
48 aggressive digital papillary adenocarcinoma 10.3 HRAS KRAS PIK3CA
49 spitz nevus 10.3 BRAF HRAS TP53
50 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.3 KRAS PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.77 HRAS KRAS PIK3CA EGFR BRAF
2 Decreased viability GR00106-A-0 10.77 KRAS
3 Decreased viability GR00221-A-1 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
4 Decreased viability GR00221-A-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.77 AKT1 FGFR3 HRAS
6 Decreased viability GR00221-A-4 10.77 AKT1 PIK3CA EGFR BRAF
7 Decreased viability GR00301-A 10.77 KRAS BRAF
8 Decreased viability GR00381-A-1 10.77 KRAS BRAF
9 Decreased viability GR00402-S-2 10.77 AKT1 FGFR3 HRAS KRAS PIK3CA EGFR
10 Decreased cell migration GR00055-A-1 9.87 AKT1 BRAF EGFR FGFR3 HRAS KRAS
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.73 EGFR FGFR2 FGFR3 HRAS PTEN PTPN11
12 Increased cell migration GR00055-A-3 9.35 BRAF EGFR HRAS KRAS PIK3CA
13 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR HRAS KRAS NFE2L2 PTEN

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 AKT1 BRAF FGFR2 FGFR3 HRAS KRAS
2 cardiovascular system MP:0005385 10.36 AKT1 BRAF EGFR FGFR2 HRAS KRAS
3 cellular MP:0005384 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
4 growth/size/body region MP:0005378 10.35 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5 homeostasis/metabolism MP:0005376 10.34 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6 integument MP:0010771 10.31 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
7 digestive/alimentary MP:0005381 10.3 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
8 embryo MP:0005380 10.29 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
9 immune system MP:0005387 10.29 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
10 adipose tissue MP:0005375 10.28 AKT1 BRAF EGFR FGFR2 NFE2L2 PIK3CA
11 endocrine/exocrine gland MP:0005379 10.28 AKT1 BRAF EGFR FGFR2 HRAS KRAS
12 craniofacial MP:0005382 10.26 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
13 neoplasm MP:0002006 10.26 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
14 nervous system MP:0003631 10.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
15 liver/biliary system MP:0005370 10.16 AKT1 BRAF EGFR FGFR2 KRAS NFE2L2
16 muscle MP:0005369 10.15 AKT1 BRAF EGFR FGFR2 KRAS PIK3CA
17 normal MP:0002873 10.14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
18 limbs/digits/tail MP:0005371 10.13 BRAF EGFR FGFR2 FGFR3 KRAS PTEN
19 hearing/vestibular/ear MP:0005377 10.11 BRAF EGFR FGFR2 FGFR3 KRAS PTPN11
20 no phenotypic analysis MP:0003012 10.03 EGFR FGFR2 FGFR3 HRAS KRAS PIK3CA
21 renal/urinary system MP:0005367 9.97 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
22 reproductive system MP:0005389 9.96 AKT1 BRAF EGFR FGFR2 FGFR3 KRAS
23 pigmentation MP:0001186 9.91 BRAF EGFR FGFR2 KRAS PTEN PTPN11
24 respiratory system MP:0005388 9.9 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
25 skeleton MP:0005390 9.73 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
26 vision/eye MP:0005391 9.28 BRAF EGFR FGFR2 FGFR3 KRAS PIK3CA

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 114977-28-5 148124
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
3
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
7
Nedaplatin Approved, Investigational Phase 4,Phase 3 95734-82-0
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
11 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 tyrosine Phase 4,Phase 3,Phase 2,Phase 1
13 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
14 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
17
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
18 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
19 Folate Phase 4,Phase 3,Phase 2,Phase 1
20 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
24 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28
Cyclophosphamide Approved, Investigational Phase 3,Phase 1 6055-19-2, 50-18-0 2907
29
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
30
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
31
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
32
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
33
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
34
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
35
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
36
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
37
Nivolumab Approved Phase 3,Phase 2 946414-94-4
38 Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6
39
Palbociclib Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 571190-30-2 11431660 5330286 5005498
40
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
41
Ponatinib Approved, Investigational Phase 2, Phase 3 943319-70-8 24826799
42
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
43
Iniparib Investigational Phase 3 160003-66-7
44
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
45
Tremelimumab Investigational Phase 2, Phase 3 745013-59-6
46 Etoposide phosphate Phase 3,Phase 2,Phase 1
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 225)
# Name Status NCT ID Phase Drugs
1 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
2 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
3 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
4 Apatinib for Advanced Lung Squmamous Carcinoma Not yet recruiting NCT03725423 Phase 4 Apatinib
5 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
6 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
7 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
8 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
9 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
10 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
11 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3 Erlotinib;Docetaxel
12 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
13 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
14 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
16 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
17 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
18 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
19 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
20 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
21 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
22 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
23 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
24 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
25 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
26 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
27 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
28 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
29 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3 Docetaxel;Erlotinib Hydrochloride;FGFR Inhibitor AZD4547;Palbociclib;Talazoparib;Taselisib
30 A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC Recruiting NCT03150875 Phase 3 Docetaxel
31 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
32 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
33 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
34 Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2, Phase 3 Docetaxel
35 Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Active, not recruiting NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
36 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
37 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
38 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
39 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
40 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
41 Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer Not yet recruiting NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
42 Photodynamic Therapy for the Prevention of Lung Cancer Not yet recruiting NCT03346304 Phase 2, Phase 3
43 Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer Not yet recruiting NCT03351361 Phase 3 Nivolumab + Ipilimumab;Chemotherapy
44 A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Not yet recruiting NCT03668496 Phase 3 SHR-1210;The placebo
45 Ponatinib for Squamous Cell Lung and Head and Neck Cancers Terminated NCT01761747 Phase 2, Phase 3 ponatinib
46 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
47 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
48 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
49 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
50 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Genetic tests related to Lung Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Lung Carcinoma 29

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

41
Lung, T Cells, Bone, Brain, Heart, Skin, Colon

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 435)
# Title Authors Year
1
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
2
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma. ( 29891994 )
2018
3
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. ( 29748009 )
2018
4
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. ( 29920955 )
2018
5
Correction: Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. ( 29437123 )
2018
6
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
7
LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. ( 29756998 )
2018
8
Secondary Hypertrophic Osteoarthropathy Associated With Pediatric Primary Lung Squamous Cell Carcinoma. ( 29652703 )
2018
9
Farrerol overcomes the invasiveness of lung squamous cell carcinoma cells by regulating the expression of inducers of epithelial mesenchymal transition. ( 29731224 )
2018
10
Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma. ( 29720381 )
2018
11
TRIM58/cg26157385 methylation is associated with eight prognostic genes in lung squamous cell carcinoma. ( 29749538 )
2018
12
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 29384143 )
2018
13
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. ( 29763624 )
2018
14
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction. ( 29853661 )
2018
15
Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. ( 29805594 )
2018
16
17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells. ( 29953987 )
2018
17
Macrophage inducible nitric oxide synthase promotes the initiation of lung squamous cell carcinoma by maintaining circulated inflammation. ( 29844374 )
2018
18
The anti-tumor effect of regorafenib in lung squamous cell carcinoma inA vitro. ( 29944884 )
2018
19
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. ( 29318765 )
2018
20
Identification of a progression-associated long non-coding RNA signature for predicting the prognosis of lung squamous cell carcinoma. ( 29434705 )
2018
21
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. ( 29902295 )
2018
22
Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. ( 29286099 )
2018
23
Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type. ( 29866243 )
2018
24
Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. ( 29305708 )
2018
25
Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. ( 29725421 )
2018
26
Integrated genomic analyses of lung squamous cell carcinoma for identification of a possible competitive endogenous RNA network by means of TCGA datasets. ( 29340250 )
2018
27
Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. ( 29673101 )
2018
28
Lung squamous cell carcinoma associated with hypoparathyroidism with sensorineural deafness and renal dysplasia syndrome: a case report. ( 29593425 )
2018
29
CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma. ( 29285191 )
2018
30
m<sup>6</sup>A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. ( 29842885 )
2018
31
Lung squamous cell carcinoma cells express non-canonically glycosylated IgG that activates integrin-FAK signaling. ( 29778566 )
2018
32
The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates. ( 30549039 )
2018
33
Discriminating lung adenocarcinoma from lung squamous cell carcinoma using respiration-induced tumor shape changes. ( 30403196 )
2018
34
UBE2D1 RNA Expression Was an Independent Unfavorable Prognostic Indicator in Lung Adenocarcinoma, but Not in Lung Squamous Cell Carcinoma. ( 30420903 )
2018
35
Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. ( 30128019 )
2018
36
Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing. ( 29129434 )
2018
37
Curcumin Inhibits Growth of Human NCI-H292 Lung Squamous Cell Carcinoma Cells by Increasing FOXA2 Expression. ( 29456509 )
2018
38
Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. ( 29459639 )
2018
39
Novel mutational landscapes and expression signatures of lung squamous cell carcinoma. ( 29484121 )
2018
40
Investigation of relationship between precursor of miRNA-944 and its mature form in lung squamous-cell carcinoma - the diagnostic value. ( 29496309 )
2018
41
Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. ( 29500362 )
2018
42
Claudin-3 Inhibits Lung Squamous Cell Carcinoma Cell Epithelial-mesenchymal Transition and Invasion via Suppression of the Wnt/β-catenin Signaling Pathway. ( 29511369 )
2018
43
Identification of key genes and long non‑coding RNAs in celecoxib‑treated lung squamous cell carcinoma cell line by RNA‑sequencing. ( 29512696 )
2018
44
Clinical significance of FAP-α on microvessel and lymphatic vessel density in lung squamous cell carcinoma. ( 29559517 )
2018
45
Long non-coding RNAs RP5-821D11.7, APCDD1L-AS1 and RP11-277P12.9 were associated with the prognosis of lung squamous cell carcinoma. ( 29568882 )
2018
46
Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese. ( 29578153 )
2018
47
Clinical significance of high expression of miR-452-5p in lung squamous cell carcinoma. ( 29616113 )
2018
48
EGFR mutations subset in Chinese lung squamous cell carcinoma patients. ( 29620244 )
2018
49
Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation. ( 29636077 )
2018
50
Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma. ( 29636867 )
2018

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 547)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
20 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
21 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
24 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
25 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
26 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
27 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
28 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
29 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
30 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
31 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh37 Chromosome 10, 123279562: 123279562
32 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic rs121918499 GRCh38 Chromosome 10, 121520048: 121520048
33 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
34 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
35 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
36 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
37 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
38 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
39 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
40 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
41 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
42 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
44 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
45 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
46 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
47 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
48 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
49 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
50 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 5111)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 2:135200405-135200405 16
2 COSM4987559 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 16
3 COSM6490907 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 16
4 COSM6491476 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 16
5 COSM6491424 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 16
6 COSM6492724 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 16
7 COSM6492589 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 16
8 COSM6492792 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 16
9 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 16:2002647-2002647 16
10 COSM3717849 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 16
11 COSM6492197 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 16
12 COSM6492124 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 16
13 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 19:53571702-53571702 16
14 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 16
15 COSM6492895 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199T 3:147395943-147395943 16
16 COSM6492817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33V 3:147410211-147410211 16
17 COSM6492224 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 16
18 COSM6492511 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46A 3:147410250-147410250 16
19 COSM6492818 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 16
20 COSM6492896 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 16
21 COSM6491849 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 16
22 COSM6492512 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 16
23 COSM6491404 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2919G>T p.L973L 8:76707874-76707874 16
24 COSM6491202 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5661A>G p.K1887K 16:72797021-72797021 16
25 COSM6941511 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.539A>T p.K180M 16:72959607-72959607 16
26 COSM6964178 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1513G>T p.D505Y 16:72958633-72958633 16
27 COSM6938564 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.7158G>A p.M2386I 16:72795524-72795524 16
28 COSM973521 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.5830G>A p.A1944T 16:72796852-72796852 16
29 COSM6971408 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6568A>T p.K2190* 16:72796114-72796114 16
30 COSM6946347 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.4628G>A p.R1543H 16:72798054-72798054 16
31 COSM6967898 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1724A>C p.E575A 16:72958422-72958422 16
32 COSM6971764 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1867G>T p.A623S 16:72958279-72958279 16
33 COSM6491691 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.6884A>T p.Q2295L 16:72795798-72795798 16
34 COSM6934208 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.2734C>G p.P912A 16:72950951-72950951 16
35 COSM6941055 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.1282A>T p.T428S 16:72958864-72958864 16
36 COSM6492881 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.8849G>T p.R2950L 16:72793833-72793833 16
37 COSM6934209 ZFHX3 lung,NS,carcinoma,squamous cell carcinoma c.899A>G p.H300R 16:72959247-72959247 16
38 COSM6491664 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.515C>T p.T172I 2:144404913-144404913 16
39 COSM6491233 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2418C>T p.F806F 2:144398769-144398769 16
40 COSM6492147 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.2805G>A p.M935I 2:144398382-144398382 16
41 COSM6491571 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.3074G>C p.R1025T 2:144390022-144390022 16
42 COSM6492450 ZEB2 lung,NS,carcinoma,squamous cell carcinoma c.708G>T p.K236N 2:144404015-144404015 16
43 COSM95691 ZCCHC2 lung,NS,carcinoma,squamous cell carcinoma c.3073G>T p.G1025* 18:62575154-62575154 16
44 COSM95554 ZAP70 lung,NS,carcinoma,squamous cell carcinoma c.188G>A p.R63H 2:97724224-97724224 16
45 COSM95552 YWHAG lung,NS,carcinoma,squamous cell carcinoma c.113C>T p.S38L 7:76330208-76330208 16
46 COSM96294 YWHAE lung,NS,carcinoma,squamous cell carcinoma c.660C>T p.I220I 17:1354266-1354266 16
47 COSM6968831 YES1 lung,NS,carcinoma,squamous cell carcinoma c.808T>A p.W270R 18:743332-743332 16
48 COSM6944975 YES1 lung,NS,carcinoma,squamous cell carcinoma c.22G>C p.E8Q 18:756806-756806 16
49 COSM95549 YAP1 lung,NS,carcinoma,squamous cell carcinoma c.485A>G p.Q162R 11:102114307-102114307 16
50 COSM1022110 XPO1 lung,NS,carcinoma,squamous cell carcinoma c.2461C>G p.Q821E 2:61485815-61485815 16

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 177)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
2
Show member pathways
14 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
3
Show member pathways
13.84 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
4
Show member pathways
13.7 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
5
Show member pathways
13.66 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
6
Show member pathways
13.62 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
7
Show member pathways
13.55 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
8
Show member pathways
13.53 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
9
Show member pathways
13.45 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
10
Show member pathways
13.45 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
11
Show member pathways
13.41 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
12
Show member pathways
13.34 AKT1 BRAF EGFR HRAS KRAS PTEN
13
Show member pathways
13.29 AKT1 EGFR FGFR2 FGFR3 PIK3CA PTEN
14
Show member pathways
13.23 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
15
Show member pathways
13.21 AKT1 EGFR HRAS KRAS PIK3CA PTEN
16
Show member pathways
13.18 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
17
Show member pathways
13.16 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
18
Show member pathways
13.12 AKT1 EGFR HRAS KRAS PIK3CA PTEN
19
Show member pathways
13.08 AKT1 BRAF EGFR HRAS KRAS PIK3CA
20
Show member pathways
13.08 AKT1 BRAF EGFR HRAS KRAS PIK3CA
21
Show member pathways
13.07 AKT1 BRAF EGFR HRAS KRAS PIK3CA
22
Show member pathways
13.01 FGFR2 FGFR3 HRAS KRAS PIK3CA PTPN11
23
Show member pathways
13.01 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
24
Show member pathways
12.96 AKT1 BRAF HRAS KRAS PIK3CA PTEN
25
Show member pathways
12.95 AKT1 BRAF EGFR FGFR2 HRAS KRAS
26 12.94 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
27
Show member pathways
12.92 AKT1 HRAS KRAS PIK3CA TP53
28
Show member pathways
12.88 AKT1 BRAF HRAS KRAS PIK3CA PTEN
29
Show member pathways
12.86 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
30
Show member pathways
12.85 AKT1 BRAF EGFR HRAS KRAS
31
Show member pathways
12.85 AKT1 BRAF EGFR HRAS KRAS TP53
32
Show member pathways
12.84 AKT1 EGFR HRAS KRAS PIK3CA PTEN
33 12.82 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
34
Show member pathways
12.8 AKT1 BRAF EGFR HRAS KRAS
35
Show member pathways
12.8 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
36
Show member pathways
12.78 AKT1 BRAF EGFR FGFR2 HRAS KRAS
37
Show member pathways
12.77 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
38
Show member pathways
12.77 AKT1 EGFR HRAS KRAS PIK3CA PTPN11
39
Show member pathways
12.77 BRAF FGFR2 FGFR3 HRAS KRAS PIK3CA
40
Show member pathways
12.74 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
41
Show member pathways
12.72 AKT1 EGFR HRAS PIK3CA PTPN11
42
Show member pathways
12.72 AKT1 BRAF EGFR HRAS KRAS PIK3CA
43 12.7 EGFR FGFR3 HRAS KRAS PIK3CA PTEN
44
Show member pathways
12.68 AKT1 HRAS PIK3CA PTEN PTPN11
45
Show member pathways
12.67 BRAF HRAS KRAS PIK3CA PTPN11
46
Show member pathways
12.67 AKT1 HRAS KRAS PIK3CA PTEN PTPN11
47
Show member pathways
12.64 AKT1 BRAF EGFR HRAS KRAS PIK3CA
48
Show member pathways
12.62 AKT1 FGFR2 FGFR3 HRAS KRAS PIK3CA
49
Show member pathways
12.59 AKT1 HRAS KRAS PIK3CA PTPN11
50 12.59 AKT1 HRAS KRAS PIK3CA TP53

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 AKT1 EGFR FGFR2 FGFR3 HRAS KRAS
2 positive regulation of protein phosphorylation GO:0001934 9.95 AKT1 EGFR HRAS KRAS
3 peptidyl-tyrosine phosphorylation GO:0018108 9.93 BRAF EGFR FGFR2 FGFR3
4 cytokine-mediated signaling pathway GO:0019221 9.93 AKT1 KRAS PIK3CA PTPN11 TP53
5 protein autophosphorylation GO:0046777 9.92 AKT1 EGFR FGFR2 FGFR3
6 negative regulation of neuron apoptotic process GO:0043524 9.89 BRAF HRAS KRAS PIK3CA
7 positive regulation of MAPK cascade GO:0043410 9.88 EGFR FGFR2 FGFR3 HRAS
8 liver development GO:0001889 9.87 EGFR KRAS PIK3CA
9 cellular response to mechanical stimulus GO:0071260 9.87 AKT1 EGFR PTPN11
10 fibroblast growth factor receptor signaling pathway GO:0008543 9.86 FGFR2 FGFR3 PTPN11
11 Ras protein signal transduction GO:0007265 9.85 HRAS KRAS TP53
12 positive regulation of epithelial cell proliferation GO:0050679 9.85 EGFR FGFR2 HRAS
13 positive regulation of MAP kinase activity GO:0043406 9.85 EGFR HRAS KRAS
14 positive regulation of protein kinase B signaling GO:0051897 9.85 EGFR FGFR2 FGFR3 PIK3CA PTPN11
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 AKT1 EGFR FGFR2
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 AKT1 BRAF EGFR PIK3CA
17 T cell costimulation GO:0031295 9.8 AKT1 PIK3CA PTPN11
18 cellular response to drug GO:0035690 9.8 BRAF EGFR NFE2L2 TP53
19 cellular response to epidermal growth factor stimulus GO:0071364 9.78 AKT1 EGFR PTPN11
20 protein kinase B signaling GO:0043491 9.76 AKT1 PIK3CA PTEN
21 cellular response to nerve growth factor stimulus GO:1990090 9.74 AKT1 BRAF PTEN
22 positive regulation of glucose import GO:0046326 9.72 AKT1 NFE2L2 PTPN11
23 cellular response to hypoxia GO:0071456 9.72 AKT1 NFE2L2 PTEN TERC TP53
24 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.71 FGFR2 FGFR3 PIK3CA PTPN11
25 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.7 AKT1 NFE2L2
26 organ growth GO:0035265 9.7 FGFR2 PTPN11
27 regulation of multicellular organism growth GO:0040014 9.7 FGFR2 PIK3CA PTPN11
28 positive regulation of gene expression GO:0010628 9.7 AKT1 BRAF HRAS KRAS NFE2L2 PTEN
29 anoikis GO:0043276 9.69 AKT1 PIK3CA
30 negative regulation of cell size GO:0045792 9.68 AKT1 PTEN
31 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.68 EGFR TP53
32 positive regulation of phospholipase activity GO:0010518 9.68 FGFR2 FGFR3
33 endochondral bone growth GO:0003416 9.67 FGFR2 FGFR3
34 epidermal growth factor receptor signaling pathway GO:0007173 9.67 AKT1 EGFR PIK3CA PTPN11
35 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.66 AKT1 EGFR
36 regulation of axon regeneration GO:0048679 9.66 BRAF PTEN
37 response to isolation stress GO:0035900 9.65 HRAS KRAS
38 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR FGFR2 FGFR3 PIK3CA PTPN11
39 cellular response to decreased oxygen levels GO:0036294 9.6 AKT1 PTEN
40 response to UV-A GO:0070141 9.56 AKT1 EGFR
41 MAPK cascade GO:0000165 9.43 BRAF EGFR FGFR2 FGFR3 HRAS KRAS
42 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.17 BRAF EGFR FGFR2 FGFR3 HRAS PTEN
43 apoptotic process GO:0006915 10.12 AKT1 FGFR2 FGFR3 HRAS PTEN TP53
44 phosphorylation GO:0016310 10.11 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
45 protein phosphorylation GO:0006468 10.09 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
46 cell proliferation GO:0008283 10.02 AKT1 EGFR HRAS PTEN TP53
47 negative regulation of apoptotic process GO:0043066 10.02 AKT1 BRAF EGFR FGFR2 FGFR3 PTEN

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 AKT1 BRAF EGFR FGFR2 FGFR3
2 kinase activity GO:0016301 9.85 AKT1 BRAF EGFR FGFR2 FGFR3 PIK3CA
3 protein kinase binding GO:0019901 9.83 AKT1 EGFR PTEN PTPN11 TP53
4 protein tyrosine kinase activity GO:0004713 9.62 BRAF EGFR FGFR2 FGFR3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 EGFR FGFR2 FGFR3
6 nucleotide binding GO:0000166 9.5 AKT1 BRAF EGFR FGFR2 FGFR3 HRAS
7 insulin receptor substrate binding GO:0043560 9.48 PIK3CA PTPN11
8 nitric-oxide synthase regulator activity GO:0030235 9.46 AKT1 EGFR
9 1-phosphatidylinositol-3-kinase activity GO:0016303 9.46 FGFR2 FGFR3 PIK3CA PTPN11
10 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR2 FGFR3
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 EGFR FGFR2 FGFR3 PIK3CA PTPN11

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....